These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33638869)

  • 21. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2008 Nov; 112(9):3587-90. PubMed ID: 18703707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
    Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
    Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma protein binding of arsenic species in acute promyelocytic leukemia patients and their relationships with hepatic and renal function.
    Gao C; Duan R; Tian S; Pang C; Zhang H; Yang H; Hai X
    Expert Rev Clin Pharmacol; 2024 Nov; 17(11):1063-1069. PubMed ID: 39420768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
    Fukai Y; Hirata M; Ueno M; Ichikawa N; Kobayashi H; Saitoh H; Sakurai T; Kinoshita K; Kaise T; Ohta S
    Biol Pharm Bull; 2006 May; 29(5):1022-7. PubMed ID: 16651738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia.
    Liu W; Wang B; Zhao Y; Wu Z; Dong A; Chen H; Lin L; Lu J; Hai X
    Front Pharmacol; 2021; 12():647687. PubMed ID: 34122070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury.
    Gao C; Fan S; Hostetter TH; Wang W; Li J; Guo M; Zhou J; Hai X
    Br J Clin Pharmacol; 2019 Apr; 85(4):849-853. PubMed ID: 30677159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma cell-free DNA in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
    Fujihara J; Nishimoto N; Takeshita H
    Ann Clin Biochem; 2024 Jul; 61(4):248-254. PubMed ID: 37944991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells.
    Charoensuk V; Gati WP; Weinfeld M; Le XC
    Toxicol Appl Pharmacol; 2009 Aug; 239(1):64-70. PubMed ID: 19465042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
    Bankar A; Korula A; Kulkarni UP; Devasia AJ; Na F; Lionel S; Abraham A; Balasubramanian P; Janet NB; Nair SC; S S; Jeyaseelan V; N J; Prasad J; George B; Mathews V
    Br J Haematol; 2020 Apr; 189(2):269-278. PubMed ID: 31863602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
    Yoshino Y; Yuan B; Miyashita SI; Iriyama N; Horikoshi A; Shikino O; Toyoda H; Kaise T
    Anal Bioanal Chem; 2009 Jan; 393(2):689-97. PubMed ID: 19009285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
    Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J
    Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
    Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
    Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
    Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new hydride generation system applied in determination of arsenic species with ion chromatography-hydride generation-atomic fluorescence spectrometry (IC-HG-AFS).
    Wei C; Liu J
    Talanta; 2007 Sep; 73(3):540-5. PubMed ID: 19073068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    Firkin F; Roncolato F; Ho WK
    Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arsenic speciation in human organs following fatal arsenic trioxide poisoning--a case report.
    Benramdane L; Accominotti M; Fanton L; Malicier D; Vallon JJ
    Clin Chem; 1999 Feb; 45(2):301-6. PubMed ID: 9931060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.